Author:
Zhang Huatang,Weng Zhangyan,Zheng Yijuan,Zheng Minghui,Chen Wenhuang,He Haoyi,Ye Xiaoyi,Zheng Youxian,Xie Jianfeng,Zheng Kuicheng,Zhang Jiming,Zhuang Xibin,Su Zhijun,Zhou Yongjun,Yu Xueping
Abstract
AbstractEpidemiological and clinical data of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (BA.2) admitted to three designated hospitals in Quanzhou City, Fujian Province, China, were collected and analyzed. Overall, 2,541 patients infected with BA.2, comprising 1,060 asymptomatic, 1,287 mild, and 194 moderate infections, were enrolled. The percentage of moderate infections was higher in patients aged ≥ 60 years than in those aged < 18 years and 18–59 years. The median hospitalization duration was 17 days. Among the 2,541 patients, 43.52% had a clear history of close contact. The vaccination rate was 87.92%, and the percentage of asymptomatic infections was higher in vaccinated than in unvaccinated patients. Moreover, patients with underlying diseases, including hypertension and diabetes mellitus, had more moderate infections than those without underlying diseases. The three most common clinical manifestations were fever, dry cough, and sore throat. The albumin-to-globulin (A/G) ratio and lymphocyte count decreased in cases with mild and moderate infections, while procalcitonin, erythrocyte sedimentation rate, interleukin-6, D-dimer, and C4 levels increased. Advanced age, non-vaccination, and underlying comorbid diseases were high-risk factors for disease progression in patients. However, dynamic monitoring of blood routine parameters, A/G ratio, and inflammatory indicators facilitated the prediction of disease progression.
Funder
Major Health Research Project of Fujian Province
Scientific and Technological Development Project of Central Government shall guide local
Young and middle-aged Talents Training Project of Fujian Provincial Health Commission
Science and Technology Innovation Joint Project of Fujian province
Publisher
Springer Science and Business Media LLC